Effects of oxytocin and prostaglandin F(2alpha) (enzaprost) on platelet aggregation. 2002

E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
I. P. Pavlov St. Petersburg State Medical University.

The effects of uterotonic agents (oxytocin and enzaprost) on platelet aggregation in pregnant and nonpregnant women were studied by low-angle light scattering. In nonpregnant women oxytocin produced different effects on ADP-induced platelet aggregation: potentiation at low (<200 nM) and inhibition at high (>400 nM) ADP concentrations. In pregnant women oxytocin did not modulate ADP-induced platelet aggregation or this effect was negligible. Enzaprost competitively inhibited ADP-induced platelet aggregation in all examined women (inhibition constant 84.8+/-25.7 nM).

UI MeSH Term Description Entries
D007743 Labor, Obstetric The repetitive uterine contraction during childbirth which is associated with the progressive dilation of the uterine cervix (CERVIX UTERI). Successful labor results in the expulsion of the FETUS and PLACENTA. Obstetric labor can be spontaneous or induced (LABOR, INDUCED). Obstetric Labor
D010120 Oxytocics Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) Oxytocic,Oxytocic Agent,Oxytocic Drug,Uterine Stimulant,Uterine Stimulants,Oxytocic Agents,Oxytocic Drugs,Oxytocic Effect,Oxytocic Effects,Agent, Oxytocic,Agents, Oxytocic,Drug, Oxytocic,Drugs, Oxytocic,Effect, Oxytocic,Effects, Oxytocic,Stimulant, Uterine,Stimulants, Uterine
D010121 Oxytocin A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Ocytocin,Pitocin,Syntocinon
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D014592 Uterine Hemorrhage Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding. Hemorrhage, Uterine,Vaginal Bleeding,Uterine Bleeding,Bleeding, Uterine,Bleeding, Vaginal,Bleedings, Vaginal,Uterine Bleedings,Uterine Hemorrhages,Vaginal Bleedings
D015237 Dinoprost A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. PGF2,PGF2alpha,Prostaglandin F2,Prostaglandin F2alpha,9alpha,11beta-PGF2,Enzaprost F,Estrofan,PGF2 alpha,Prostaglandin F2 alpha,9alpha,11beta PGF2,F2 alpha, Prostaglandin,F2alpha, Prostaglandin,alpha, PGF2

Related Publications

E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
February 2000, Biology of reproduction,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
February 1975, The Journal of reproductive medicine,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
November 1996, Theriogenology,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
January 1978, Advances in experimental medicine and biology,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
March 2006, Prostaglandins, leukotrienes, and essential fatty acids,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
March 1974, Toxicology,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
January 2007, Animal reproduction science,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
March 1975, Prostaglandins,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
July 2002, Biology of reproduction,
E K Ailamazyan, and N N Petrishchev, and E V Vivulanets, and L V Maryutina, and I V Mindukshev, and A R Khachaturyan
June 2001, Molecular pharmacology,
Copied contents to your clipboard!